Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:29 PM
Ignite Modification Date:
2025-12-24 @ 10:29 PM
NCT ID:
NCT06772935
Eligibility Criteria:
Inclusion Criteria:
* Breast cancer patients diagnosed by pathology;
* EOOG score is 0 or 1;
* The age range for enrollment is between 18 and 75 years old; ④ Accept chemotherapy regimens based on taxane drugs (alone or in combination);
⑤ Previously received taxane chemotherapy for more than 6 months;
⑥ According to the National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) 5.0, reporting CIPN symptoms of grade 1 or higher for more than 2 weeks;
⑦ Voluntarily participate in this clinical trial and sign the informed consent form;
* Accept regular follow-up visits; ⑨ There is complete pathological data available.
Exclusion Criteria:
* Non breast cancer patients;
* Received electroacupuncture treatment within 6 months prior to the start of the study;
* Patients who experience intolerable toxic side effects during standard dose chemotherapy and terminate the chemotherapy cycle;
* Prior to enrollment, there was a history of peripheral neuropathy;
* Unstable heart disease or myocardial infarction within the first 6 months of the study;
⑥ Active skin diseases or surface skin ulcers or infections that cannot tolerate electroacupuncture treatment;
⑦ Uncontrolled epilepsy patients with uncontrolled seizures;
⑧ Merge with other malignant tumor patients;
⑨ Pregnancy and lactation period;
⑩ Refusal to join clinical trial patients
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT06772935
Study Brief:
Protocol Section:
NCT06772935